108 results on '"Rinella, Mary E."'
Search Results
2. FRI-208 qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy
3. LBP-036 Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis
4. Reply: NAFLD vs. MASLD—There ain’t no such thing as a free lunch
5. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
6. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
7. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease
8. Implementation of a liver health check in people with type 2 diabetes
9. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study
11. Reply: ‘From NAFLD to MASLD: Promise and pitfalls of a new definition’†
12. Steatotic liver disease, a useful construct in primary care that doesn’t upset the apple cart
13. Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition”
14. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
15. Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
16. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease
17. Natural history of NASH cirrhosis in liver transplant waitlist registrants
18. A global research priority agenda to advance public health responses to fatty liver disease
19. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with “Ludwig disease”
20. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis
21. Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening
22. Reply: ELF in the risk stratification of NAFLD—Are the ELF thresholds suggested by the AASLD guidelines appropriate?
23. Recurrent NAFLD post LT: sisyphus’ boulder or proteus’ parable?
24. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
25. Prebiotic activity of lactulose optimizes gut metabolites and prevents systemic infection in liver disease patients
26. Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium
27. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease
28. Research Priorities for Precision Medicine in NAFLD
29. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
30. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
31. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
32. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis
33. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
34. Nonalcoholic Fatty Liver Disease and Steatohepatitis
35. Editorial: global liver fat accumulation and global health—towards a sustainable development goal. Authors' reply
36. Fatty Liver Disease: Diagnosis and Stratification
37. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
38. Preparing for the NASH epidemic: A call to action
39. Preparing for the NASH Epidemic: A Call to Action
40. Preparing for the NASH epidemic: A call to action
41. A Sustainable Development Goal framework to guide multisectoral action on NAFLD through a societal approach
42. Preparing for the NASH Epidemic: A Call to Action
43. Preparing for the NASH Epidemic: A Call to Action
44. Preparing for the NASH Epidemic: A Call to Action
45. Real-World Burden of Nonalcoholic Steatohepatitis
46. Non-alcoholic fatty liver disease: Not time for an obituary just yet!
47. Association between history of bariatric surgery and graft rejection among solid organ transplant recipients
48. From NAFLD to MAFLD : Implications of a Premature Change in Terminology
49. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis
50. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.